Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy

Daisuke Nobuoka, Toshiaki Yoshikawa, Toshiyoshi Fujiwara, Tetsuya Nakatsura

Research output: Contribution to journalArticle

9 Citations (Scopus)


One of the problems in antigen-specific cancer immunotherapy is the low density of the tumor antigen-derived peptide endogenously presented on tumor cell surface major histocompatibility complex class I molecules. To overcome this, we are engaged in research on peptide intra-tumor injection to enhance tumor cell antigenicity. In in vivo studies using immunodeficient mice, the peptide injected into a solid mass of subcutaneous tumor was revealed to be loaded onto human leukocyte antigen class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, peptide intra-tumor injection was effective in terms of tumor growth inhibition and prolongation of survival time. Moreover, an antigen-spreading effect was detected after peptide intra-tumor injection. Peptide intra-tumor injection is an effective method of enhancing tumor cell antigenicity. It can induce additional peptide loading onto tumor cells, making tumor cells more antigenic for specific cytotoxic T-lymphocyte activity. Peptide intra-tumor injection may be a useful option for improvement of antigen-specific immunotherapy against solid tumors.

Original languageEnglish
Pages (from-to)1234-1236
Number of pages3
JournalHuman Vaccines and Immunotherapeutics
Issue number6
Publication statusPublished - Jun 2013



  • Antigen-derived peptide
  • Cancer immunotherapy
  • Cytotoxic T lymphocyte
  • Major histocompatibility complex class I
  • Tumor antigen

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this